Listen on the go
CORRECT!
Next question
touchDERMATOLOGY touchDERMATOLOGY

Start Learning

Touch Loading image
touchEXPERT BRIEFING
Start Learning
Advances in the treatment of CSU
Sponsored content
Pyoderma gangrenosum, Benjamin Kaffenberger
JOURNALS
Start Learning
Latest encouraging vilobelimab data in pyoderma gangrenosum
JOURNALS
Start Learning
FDA approval of nemolizumab gives new treatment option for prurigo nodularis
Layer of cells, human skin cells, medical illustration
JOURNALS
Start Learning
Could dupilumab help improve height in children with severe atopic dermatitis?
JOURNALS
Start Learning
Ruxolitinib cream shows safe and lasting control in paediatric atopic dermatitis
touchMDT
Start Learning
Navigating the management of cholestatic pruritus in patients with PBC: Insights from the multidisciplinary team
CE/CME ACCREDITED
touchMEETING HIGHLIGHTS
Start Learning
ADVENT at ESPD 2024: Type 2 Inflammation in Atopic Dermatitis and the Benefits of Early Intervention
Sponsored content
David Rosmarin: Tapinarof 1% in atopic dermatitis: Can patients take a drug holiday and maintain response?
CONFERENCE HUB
Start Learning
Tapinarof 1% in atopic dermatitis: Can patients take a drug holiday and maintain response?
JOURNALS
Start Learning
Journal spotlight: Recent literature highlights
JOURNALS
Start Learning
New study links rosacea with increased risk of malignant melanoma

to view Favourites, Keep Notes and Track CME Credits

Favourites
Ruxolitinib cream shows safe and lasting control in paediatric atopic dermatitis
View
New study links rosacea with increased risk of malignant melanoma
View
Tapinarof 1% in atopic dermatitis: Can patients take a drug holiday and maintain response?
View
New data in oral lichen planus shows LP-310 oral tacrolimus reduces pain, ulceration and inflammation
View
Advances in the treatment of CSU
View
Advancing Global Skin Health: How the International Society of Dermatology is bridging gaps through education, outreach and collaboration
View
Baricitinib 4 mg delivers rapid, significant hair growth in adolescents with severe alopecia areata
View
Introducing our newest Expert Faculty member: A leader in urticaria, drug allergies and angioedema
View
Latest encouraging vilobelimab data in pyoderma gangrenosum
View
Rare disease round-up: Pyoderma gangrenosum
View
Copied to clipboard!
accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72
Close Popup